human fgf acidic Search Results


92
R&D Systems goat polyclonal anti fgf1
Goat Polyclonal Anti Fgf1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Human+FGF+acidic%2FFGF1+Antibody/pmc09519926-58-33-37
Average 92 stars, based on 1 article reviews
goat polyclonal anti fgf1 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

91
Cell Signaling Technology Inc rrid ab 2739823
Rrid Ab 2739823, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Human+FGF-acidic%2FFGF1+Recombinant+Protein/pm37524800-483-64-76
Average 91 stars, based on 1 article reviews
rrid ab 2739823 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

92
R&D Systems mcf7
Manuka honey activates AMPK signaling and inhibits mTOR and STAT3 downstream signaling. ( A ) <t>MCF7</t> cells were treated with increasing concentrations of Manuka honey (0–5%) and 5% Mesquite honey as control. After 24 h, cells were lysed and immunoblotted with specific antibodies. ( B ) MCF7 cells were treated with increasing concentrations of Manuka honey 0.3–5% ( w / v ). After 24 h, cells were lysed, and whole cell extracts were resolved by PAGE and immunoblotted with specific antibodies.
Mcf7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Recombinant+Human+FGF+acidic%2FFGF1+(aa+2-155)+Protein/pmc11279598-63-0-67
Average 92 stars, based on 1 article reviews
mcf7 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

94
R&D Systems recombinant human fgf1 acidic
Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and <t>recombinant</t> GF at a concentration of 20 ng/mL <t>(FGF1/2),</t> 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also <xref ref-type=Figure S4 and . " width="250" height="auto" />
Recombinant Human Fgf1 Acidic, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Recombinant+Human+FGF+acidic%2FFGF1+(aa+16-155)+Protein/pmc06617392-24-0-5
Average 94 stars, based on 1 article reviews
recombinant human fgf1 acidic - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
R&D Systems human fgf1 immunoassay elisa kit
Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and <t>recombinant</t> GF at a concentration of 20 ng/mL <t>(FGF1/2),</t> 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also <xref ref-type=Figure S4 and . " width="250" height="auto" />
Human Fgf1 Immunoassay Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Human+FGF+acidic%2FFGF1+DuoSet+ELISA/pmc05852627-235-25-30
Average 90 stars, based on 1 article reviews
human fgf1 immunoassay elisa kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
R&D Systems r d recombinant human fgf acidic aa
Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and <t>recombinant</t> GF at a concentration of 20 ng/mL <t>(FGF1/2),</t> 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also <xref ref-type=Figure S4 and . " width="250" height="auto" />
R D Recombinant Human Fgf Acidic Aa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Recombinant+Human+FGF+acidic%2FFGF1+(aa+2-155)+Protein%2C+CF/us09567385-83-58-70
Average 94 stars, based on 1 article reviews
r d recombinant human fgf acidic aa - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
MedChemExpress human mce cat
Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and <t>recombinant</t> GF at a concentration of 20 ng/mL <t>(FGF1/2),</t> 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also <xref ref-type=Figure S4 and . " width="250" height="auto" />
Human Mce Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/FGF-1%2C+Human/pm42599803-266-24-25
Average 94 stars, based on 1 article reviews
human mce cat - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
R&D Systems human fgf acidic
Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and <t>recombinant</t> GF at a concentration of 20 ng/mL <t>(FGF1/2),</t> 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also <xref ref-type=Figure S4 and . " width="250" height="auto" />
Human Fgf Acidic, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Recombinant+Human+FGF+acidic%2FFGF1+(aa+16-155)+Protein/pm41075247-764-22-28
Average 93 stars, based on 1 article reviews
human fgf acidic - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems goat polyclonal
List of primary antibodies used for immunohistochemistry.
Goat Polyclonal, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Human+FGF+acidic%2FFGF1+Antibody/pmc09087371-1-2-7
Average 93 stars, based on 1 article reviews
goat polyclonal - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems serum fgf1 levels
Clinical characteristics of individuals with undetectable and detectable <t> serum FGF1 levels. </t>
Serum Fgf1 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Human+FGF+acidic%2FFGF1+Quantikine+ELISA+Kit/pmc10239951-87-0-13
Average 94 stars, based on 1 article reviews
serum fgf1 levels - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
R&D Systems elisa assay
Clinical characteristics of individuals with undetectable and detectable <t> serum FGF1 levels. </t>
Elisa Assay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Human+FGF+acidic%2FFGF1+Quantikine+ELISA+Kit/pm26771970-65-9-11
Average 94 stars, based on 1 article reviews
elisa assay - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Shanghai Korain Biotech Co Ltd human elisa kits
Clinical characteristics of individuals with undetectable and detectable <t> serum FGF1 levels. </t>
Human Elisa Kits, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf+acidic/Human+Fibroblast+Growth+Factor+1/10__14740_slash_jem1595-94-9-36
Average 94 stars, based on 1 article reviews
human elisa kits - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Manuka honey activates AMPK signaling and inhibits mTOR and STAT3 downstream signaling. ( A ) MCF7 cells were treated with increasing concentrations of Manuka honey (0–5%) and 5% Mesquite honey as control. After 24 h, cells were lysed and immunoblotted with specific antibodies. ( B ) MCF7 cells were treated with increasing concentrations of Manuka honey 0.3–5% ( w / v ). After 24 h, cells were lysed, and whole cell extracts were resolved by PAGE and immunoblotted with specific antibodies.

Journal: Nutrients

Article Title: Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models

doi: 10.3390/nu16142369

Figure Lengend Snippet: Manuka honey activates AMPK signaling and inhibits mTOR and STAT3 downstream signaling. ( A ) MCF7 cells were treated with increasing concentrations of Manuka honey (0–5%) and 5% Mesquite honey as control. After 24 h, cells were lysed and immunoblotted with specific antibodies. ( B ) MCF7 cells were treated with increasing concentrations of Manuka honey 0.3–5% ( w / v ). After 24 h, cells were lysed, and whole cell extracts were resolved by PAGE and immunoblotted with specific antibodies.

Article Snippet: MCF7 and MDA-MB-231 BC cells were cultured in 6-well plates at a concentration of 250,000 cells/well for 24 h. The next day, cells were treated with either 2.5% MH, 5.0% MH, 5.0% dextrose, 5.0% Mesquite honey, or 10 μM Camptothecin for 24 and 48 h. Cells were collected with AccutaseTM cell dissociation reagent, washed and stained using an Annexin V-FITC and 7-AAD Dead Cell Apoptosis Detection Kit (R&D Systems), and analyzed using flow cytometry.

Techniques: Control

Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and recombinant GF at a concentration of 20 ng/mL (FGF1/2), 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also <xref ref-type=Figure S4 and . " width="100%" height="100%">

Journal: Cancer Cell

Article Title: Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

doi: 10.1016/j.ccell.2019.05.013

Figure Lengend Snippet: Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and recombinant GF at a concentration of 20 ng/mL (FGF1/2), 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also Figure S4 and .

Article Snippet: Recombinant human FGF1 acidic , RnD Systems , Cat# 232-FA-025.

Techniques: Quantitative Proteomics, Western Blot, Expressing, Growth Assay, Recombinant, Concentration Assay

Journal: Cancer Cell

Article Title: Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

doi: 10.1016/j.ccell.2019.05.013

Figure Lengend Snippet:

Article Snippet: Recombinant human FGF1 acidic , RnD Systems , Cat# 232-FA-025.

Techniques: Control, Recombinant, Sequencing, Software

List of primary antibodies used for immunohistochemistry.

Journal: European Journal of Histochemistry : EJH

Article Title: Secreted key regulators (Fgf1, Bmp4, Gdf3) are expressed by PAC1-immunopositive retinal ganglion cells in the postnatal rat retina

doi: 10.4081/ejh.2022.3373

Figure Lengend Snippet: List of primary antibodies used for immunohistochemistry.

Article Snippet: anti-Fgf1 , Goat polyclonal , 1:1000 , RDsystems, Budapest, Hungary (AF232).

Techniques: Immunohistochemistry

Clinical characteristics of individuals with undetectable and detectable  serum FGF1 levels.

Journal: Frontiers in Endocrinology

Article Title: Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance

doi: 10.3389/fendo.2023.1198311

Figure Lengend Snippet: Clinical characteristics of individuals with undetectable and detectable serum FGF1 levels.

Article Snippet: Serum FGF1 levels were examined using an enzyme-linked immunosorbent assay (catalog no. DFA00B; R&D Systems, Inc., Minneapolis, MN USA).

Techniques:

Metabolic parameters of individuals with undetectable (group 1), low (group 2), and high (group 3)  serum FGF1 levels.

Journal: Frontiers in Endocrinology

Article Title: Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance

doi: 10.3389/fendo.2023.1198311

Figure Lengend Snippet: Metabolic parameters of individuals with undetectable (group 1), low (group 2), and high (group 3) serum FGF1 levels.

Article Snippet: Serum FGF1 levels were examined using an enzyme-linked immunosorbent assay (catalog no. DFA00B; R&D Systems, Inc., Minneapolis, MN USA).

Techniques:

Metabolic parameters of individuals with undetectable (group 1), low (group 2), and high (group 3) serum FGF1 levels. DI, disposition index; IGI, insulinogenic index; ISI, Matsuda insulin sensitivity index.

Journal: Frontiers in Endocrinology

Article Title: Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance

doi: 10.3389/fendo.2023.1198311

Figure Lengend Snippet: Metabolic parameters of individuals with undetectable (group 1), low (group 2), and high (group 3) serum FGF1 levels. DI, disposition index; IGI, insulinogenic index; ISI, Matsuda insulin sensitivity index.

Article Snippet: Serum FGF1 levels were examined using an enzyme-linked immunosorbent assay (catalog no. DFA00B; R&D Systems, Inc., Minneapolis, MN USA).

Techniques:

Univariable and multivariable analysis of the association between  serum FGF1 levels  and metabolic parameters using a Tobit regression model.

Journal: Frontiers in Endocrinology

Article Title: Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance

doi: 10.3389/fendo.2023.1198311

Figure Lengend Snippet: Univariable and multivariable analysis of the association between serum FGF1 levels and metabolic parameters using a Tobit regression model.

Article Snippet: Serum FGF1 levels were examined using an enzyme-linked immunosorbent assay (catalog no. DFA00B; R&D Systems, Inc., Minneapolis, MN USA).

Techniques:

Box plot of the estimated log-transformed serum FGF1 level according to the quartile of each parameter using a Tobit regression model adjusted by age and sex. DI, disposition index; IGI, insulinogenic index; ISI, Matsuda insulin sensitivity index.

Journal: Frontiers in Endocrinology

Article Title: Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance

doi: 10.3389/fendo.2023.1198311

Figure Lengend Snippet: Box plot of the estimated log-transformed serum FGF1 level according to the quartile of each parameter using a Tobit regression model adjusted by age and sex. DI, disposition index; IGI, insulinogenic index; ISI, Matsuda insulin sensitivity index.

Article Snippet: Serum FGF1 levels were examined using an enzyme-linked immunosorbent assay (catalog no. DFA00B; R&D Systems, Inc., Minneapolis, MN USA).

Techniques: Transformation Assay